Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies
JI Odegaard, JJ Vincent, S Mortimer, JV Vowles… - Clinical Cancer …, 2018 - AACR
Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
test for comprehensive tumor genotyping and demonstrate its clinical feasibility …
[HTML][HTML] The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of …
Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …
with NSCLC and have led to unprecedented improvements in response rates and survival in …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel
J Willis, MI Lefterova, A Artyomenko, PM Kasi… - Clinical Cancer …, 2019 - AACR
Purpose: To analytically and clinically validate microsatellite instability (MSI) detection using
cell-free DNA (cfDNA) sequencing. Experimental Design: Pan-cancer MSI detection using …
cell-free DNA (cfDNA) sequencing. Experimental Design: Pan-cancer MSI detection using …
Mechanisms of osimertinib resistance and emerging treatment options
S Schmid, JJN Li, NB Leighl - Lung Cancer, 2020 - Elsevier
Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment
of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting …
of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting …
Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance
D Stetson, A Ahmed, X Xu, BRB Nuttall… - JCO Precision …, 2019 - ascopubs.org
PURPOSE Discordance between plasma and tumor variant calling has been attributed
primarily to tumor heterogeneity, whereas technical variables remain largely unexplored …
primarily to tumor heterogeneity, whereas technical variables remain largely unexplored …